NASDAQ · XBIT
Healthcare · Biotechnology
$2.33
Up+$0.02 (+0.64%)
Updated Aug 14, 2026, 7:13 PM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
XBIT closed at $2.33 after 21 trading sessions, up 1.75% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $2.44 | $2.47 | $2.3073 | $2.33 | 41.68K |
| Aug 12, 2026 | $2.35 | $2.46 | $2.29 | $2.46 | 58.62K |
| Aug 11, 2026 | $2.28 | $2.35 | $2.25 | $2.33 | 22.45K |
| Aug 10, 2026 | $2.27 | $2.295 | $2.27 | $2.28 | 4.59K |
| Aug 7, 2026 | $2.27 | $2.29 | $2.27 | $2.27 | 15.35K |
| Aug 6, 2026 | $2.28 | $2.28 | $2.255 | $2.28 | 9.96K |
| Aug 5, 2026 | $2.26 | $2.28 | $2.23 | $2.26 | 35.32K |
| Aug 4, 2026 | $2.24 | $2.29 | $2.23 | $2.24 | 28.41K |
| Aug 3, 2026 | $2.2201 | $2.25 | $2.22 | $2.235 | 12.83K |
| Jul 31, 2026 | $2.25 | $2.2572 | $2.22 | $2.23 | 37.8K |
| Jul 30, 2026 | $2.25 | $2.25 | $2.24 | $2.24 | 6.99K |
| Jul 29, 2026 | $2.27 | $2.315 | $2.245 | $2.25 | 35.56K |
| Jul 28, 2026 | $2.26 | $2.31 | $2.2555 | $2.27 | 16.37K |
| Jul 27, 2026 | $2.26 | $2.27 | $2.25 | $2.26 | 30.06K |
| Jul 24, 2026 | $2.29 | $2.29 | $2.25 | $2.27 | 22.16K |
| Jul 23, 2026 | $2.27 | $2.29 | $2.27 | $2.28 | 24.69K |
| Jul 22, 2026 | $2.24 | $2.31 | $2.19 | $2.27 | 107.56K |
| Jul 21, 2026 | $2.25 | $2.27 | $2.19 | $2.24 | 106.91K |
| Jul 20, 2026 | $2.28 | $2.29 | $2.235 | $2.25 | 44.12K |
| Jul 17, 2026 | $2.28 | $2.282 | $2.25 | $2.27 | 59.1K |
| Jul 16, 2026 | $2.30 | $2.3089 | $2.28 | $2.29 | 21.91K |
The latest Smart Investors Daily articles mentioning XBIT.
XBIT research
Company profile and research snapshot.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 7, 2020 | Piper Sandler | Overweight | — |
| Dec 11, 2019 | PiperJaffray | Overweight | — |
| Jun 14, 2019 | Piper Jaffray | Overweight | — |
No generated briefing is available yet.
defenseworld.net · Dec 6, 2025
XBiotech Inc. (NASDAQ: XBIT - Get Free Report) passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $2.47 and traded as high as $2.68. XBiotech shares last traded at $2.48, with a volume of 87,170 shares changing hands. Analyst Upgrades and Downgrades Separately, Weiss
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XBIT.
No results
No recent SID articles mention XBIT.
